Back to results
US 2018/0022734 A1Published application
Sunitinib prodrug and pharmaceutical composition
AssigneeSound Biopharmaceuticals Co. Ltd.
InventorsZhong Wang, Qing Li
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSound Biopharmaceuticals Co. Ltd.
InventorsZhong Wang, Qing Li
Estimating the term…
The present invention provides a Sunitinib prodrug having formula I, wherein R12, R13 are selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl and 5-15 membered heteroaryl; R14 is selected from the group consisting of R′, OR′, SR′ and N(R′)2; and R′ is selected from the group consisting of H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C8 cycloalkyl, C6-C10 aryl, 4-15 membered heterocyclyl, 5-15 membered heteroaryl, hydroxyl C1-C6 alkyl, carboxyl C1-C6 alkyl, C1-C6 alkyl amido and phosphate group. The Sunitinib prodrug of the invention provides better pharmacokinetics and pharmacodynamics, better safety and lower toxicity.
A compound having formula I:
A compound selected from the group consisting of:
Dependencies are inferred from the claim text.